{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:07:57Z","timestamp":1794438477319,"version":"4.9.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["AG071332"],"award-info":[{"award-number":["AG071332"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67608-5","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:45:02Z","timestamp":1766177102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Structural determinants of non-covalent PPAR\u03b3 inverse agonism and their therapeutic implications"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1593-1406","authenticated-orcid":false,"given":"Kuang-Ting","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilel","family":"Bdiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben D.","family":"Garcia-Ordonez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-6789","authenticated-orcid":false,"given":"Daniel P.","family":"McDougal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ra","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-4775","authenticated-orcid":false,"given":"Michael D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-1824","authenticated-orcid":false,"given":"John B.","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore M.","family":"Kamenecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-690X","authenticated-orcid":false,"given":"Patrick R.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"67608_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.615375","volume":"10","author":"T Scully","year":"2020","unstructured":"Scully, T., Ettela, A., LeRoith, D. & Gallagher, E. J. Obesity, type 2 diabetes, and cancer risk. Front. Oncol. 10, 615375 (2020).","journal-title":"Front. Oncol."},{"key":"67608_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","volume":"9","author":"X Lu","year":"2024","unstructured":"Lu, X. et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct. Target Ther. 9, 262 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"67608_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01761-4","author":"S Corrao","year":"2025","unstructured":"Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S. & Calvo, L. Type 2 diabetes mellitus remission, dream or reality? A narrative review of current evidence and integrated care strategies. Diab. Ther. https:\/\/doi.org\/10.1007\/s13300-025-01761-4 (2025).","journal-title":"Diab. Ther."},{"key":"67608_CR4","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice, C. 10","year":"2025","unstructured":"American Diabetes Association Professional Practice, C. 10 Cardiovascular disease and risk management: standards of care in diabetes\u20142025. Diab. Care 48, S207\u2013S238 (2025).","journal-title":"Diab. Care"},{"key":"67608_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ijerph22060910","volume":"22","author":"O Ojo","year":"2025","unstructured":"Ojo, O. et al. The effect of type 2 diabetes on bone quality: a systematic review and meta-analysis of cohort studies. Int. J. Environ. Res. Public Health 22, 910 (2025).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"67608_CR6","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.3390\/ijms26125669","volume":"26","author":"M Pliszka","year":"2025","unstructured":"Pliszka, M. & Szablewski, L. Severe insulin resistance syndromes: clinical spectrum and management. Int. J. Mol. Sci. 26, 5669 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"67608_CR7","doi-asserted-by":"publisher","first-page":"e002146","DOI":"10.1136\/bmjdrc-2021-002146","volume":"9","author":"A Gonzalez-Perez","year":"2021","unstructured":"Gonzalez-Perez, A., Saez, M., Vizcaya, D., Lind, M. & Garcia Rodriguez, L. Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. BMJ Open Diab. Res. Care 9, e002146 (2021).","journal-title":"BMJ Open Diab. Res. Care"},{"key":"67608_CR8","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1210\/en.2006-1587","volume":"148","author":"OP Lazarenko","year":"2007","unstructured":"Lazarenko, O. P. et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148, 2669\u20132680 (2007).","journal-title":"Endocrinology"},{"key":"67608_CR9","first-page":"895","volume":"20","author":"IM Breunig","year":"2014","unstructured":"Breunig, I. M., Shaya, F. T., McPherson, M. L. & Snitker, S. Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. J. Manag Care Spec. Ph. 20, 895\u2013903 (2014).","journal-title":"J. Manag Care Spec. Ph."},{"key":"67608_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.624112","volume":"12","author":"M Hernandez-Quiles","year":"2021","unstructured":"Hernandez-Quiles, M., Broekema, M. F. & Kalkhoven, E. PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Front. Endocrinol. (Lausanne) 12, 624112 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"67608_CR11","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.2174\/0929867327666200716113136","volume":"28","author":"S Mal","year":"2021","unstructured":"Mal, S. et al. Role of peroxisome proliferator-activated receptor gamma (PPARgamma) in different disease states: recent updates. Curr. Med. Chem. 28, 3193\u20133215 (2021).","journal-title":"Curr. Med. Chem."},{"key":"67608_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11892-021-01385-5","volume":"21","author":"S Cataldi","year":"2021","unstructured":"Cataldi, S., Costa, V., Ciccodicola, A. & Aprile, M. PPARgamma and diabetes: beyond the genome and towards personalized medicine. Curr. Diab. Rep. 21, 18 (2021).","journal-title":"Curr. Diab. Rep."},{"key":"67608_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jare.2020.01.008","volume":"23","author":"G Bansal","year":"2020","unstructured":"Bansal, G., Thanikachalam, P. V., Maurya, R. K., Chawla, P. & Ramamurthy, S. An overview on medicinal perspective of thiazolidine-2,4-dione: a remarkable scaffold in the treatment of type 2 diabetes. J. Adv. Res. 23, 163\u2013205 (2020).","journal-title":"J. Adv. Res."},{"key":"67608_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne, D., Butruille, L. & Staels, B. PPAR control of metabolism and cardiovascular functions. Nat. Rev. Cardiol. 18, 809\u2013823 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"67608_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","volume":"32","author":"JA Hall","year":"2020","unstructured":"Hall, J. A. et al. Obesity-linked PPARgamma S273 phosphorylation promotes insulin resistance through growth differentiation factor 3. Cell Metab. 32, 665\u2013675 e666 (2020).","journal-title":"Cell Metab."},{"key":"67608_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.biochi.2017.11.014","volume":"146","author":"SS Anusree","year":"2018","unstructured":"Anusree, S. S., Sindhu, G., Preetha Rani, M. R. & Raghu, K. G. Insulin resistance in 3T3-L1 adipocytes by TNF-alpha is improved by punicic acid through upregulation of insulin signalling pathway and endocrine function, and downregulation of proinflammatory cytokines. Biochimie 146, 79\u201386 (2018).","journal-title":"Biochimie"},{"key":"67608_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","volume":"9","author":"C Janani","year":"2015","unstructured":"Janani, C. & Ranjitha Kumari, B. D. PPAR gamma gene-a review. Diab. Metab. Syndr. 9, 46\u201350 (2015).","journal-title":"Diab. Metab. Syndr."},{"key":"67608_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbrc.2016.10.152","volume":"481","author":"D Li","year":"2016","unstructured":"Li, D. et al. Distinct functions of PPARgamma isoforms in regulating adipocyte plasticity. Biochem. Biophys. Res. Commun. 481, 132\u2013138 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"67608_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106324","volume":"182","author":"H Zou","year":"2022","unstructured":"Zou, H. et al. Nuclear receptor RORgamma inverse agonists\/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy. Pharm. Res. 182, 106324 (2022).","journal-title":"Pharm. Res."},{"key":"67608_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02891-2","volume":"11","author":"J Tan","year":"2020","unstructured":"Tan, J. et al. Small molecules targeting RORgammat inhibit autoimmune disease by suppressing Th17 cell differentiation. Cell Death Dis. 11, 697 (2020).","journal-title":"Cell Death Dis."},{"key":"67608_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1021\/acschembio.9b00236","volume":"14","author":"MR Chang","year":"2019","unstructured":"Chang, M. R. et al. Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways. ACS Chem. Biol. 14, 1051\u20131062 (2019).","journal-title":"ACS Chem. Biol."},{"key":"67608_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bcp.2018.01.023","volume":"150","author":"A Shibata","year":"2018","unstructured":"Shibata, A. et al. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORgammat inverse agonist. Biochem. Pharm. 150, 35\u201345 (2018).","journal-title":"Biochem. Pharm."},{"key":"67608_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi, J. H. et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466, 451\u2013456 (2010).","journal-title":"Nature"},{"key":"67608_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature10383","volume":"477","author":"JH Choi","year":"2011","unstructured":"Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477\u2013481 (2011).","journal-title":"Nature"},{"key":"67608_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1021\/acsmedchemlett.5b00218","volume":"6","author":"A Asteian","year":"2015","unstructured":"Asteian, A. et al. Design, synthesis, and biological evaluation of indole biphenylcarboxylic acids as PPARgamma antagonists. ACS Med Chem. Lett. 6, 998\u20131003 (2015).","journal-title":"ACS Med Chem. Lett."},{"key":"67608_CR26","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.str.2018.07.007","volume":"26","author":"J Zheng","year":"2018","unstructured":"Zheng, J. et al. Chemical crosslinking mass spectrometry reveals the conformational landscape of the activation helix of PPARgamma; a model for ligand-dependent antagonism. Structure 26, 1431\u20131439 e1436 (2018).","journal-title":"Structure"},{"key":"67608_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.isci.2018.06.012","volume":"5","author":"RL Frkic","year":"2018","unstructured":"Frkic, R. L. et al. PPARgamma in complex with an antagonist and inverse agonist: a tumble and trap mechanism of the activation helix. iScience 5, 69\u201379 (2018).","journal-title":"iScience"},{"key":"67608_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ebiom.2016.06.040","volume":"10","author":"LA Stechschulte","year":"2016","unstructured":"Stechschulte, L. A. et al. PPARG post-translational modifications regulate bone formation and bone resorption. EBioMedicine 10, 174\u2013184 (2016).","journal-title":"EBioMedicine"},{"key":"67608_CR29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1021\/acschembio.2c00917","volume":"18","author":"RL Frkic","year":"2023","unstructured":"Frkic, R. L. et al. PPARgamma corepression involves alternate ligand conformation and inflation of H12 ensembles. ACS Chem. Biol. 18, 1115\u20131123 (2023).","journal-title":"ACS Chem. Biol."},{"key":"67608_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8443","volume":"6","author":"DP Marciano","year":"2015","unstructured":"Marciano, D. P. et al. Pharmacological repression of PPARgamma promotes osteogenesis. Nat. Commun. 6, 7443 (2015).","journal-title":"Nat. Commun."},{"key":"67608_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbrc.2019.10.048","volume":"520","author":"YH Kim","year":"2019","unstructured":"Kim, Y. H. et al. Fenofibrate induces PPARalpha and BMP2 expression to stimulate osteoblast differentiation. Biochem. Biophys. Res. Commun. 520, 459\u2013465 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"67608_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/sctm.17-0098","volume":"7","author":"L Vergori","year":"2018","unstructured":"Vergori, L., Lauret, E., Soleti, R., Andriantsitohaina, R. & Carmen Martinez, M. Microparticles carrying peroxisome proliferator-activated receptor alpha restore the reduced differentiation and functionality of bone marrow-derived cells induced by high-fat diet. Stem Cells Transl. Med 7, 135\u2013145 (2018).","journal-title":"Stem Cells Transl. Med"},{"key":"67608_CR33","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.tem.2010.08.006","volume":"21","author":"Y Wan","year":"2010","unstructured":"Wan, Y. PPARgamma in bone homeostasis. Trends Endocrinol. Metab. 21, 722\u2013728 (2010).","journal-title":"Trends Endocrinol. Metab."},{"key":"67608_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145467","volume":"14","author":"A Chougule","year":"2023","unstructured":"Chougule, A. et al. Osteocytes contribute via nuclear receptor PPAR-alpha to maintenance of bone and systemic energy metabolism. Front. Endocrinol. (Lausanne) 14, 1145467 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"67608_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/25931","volume":"395","author":"RT Nolte","year":"1998","unstructured":"Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-\u03b3. Nature 395, 137\u2013143 (1998).","journal-title":"Nature"},{"key":"67608_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17082-x","volume":"7","author":"MA Lee","year":"2017","unstructured":"Lee, M. A., Tan, L., Yang, H., Im, Y. G. & Im, Y. J. Structures of PPARgamma complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Sci. Rep. 7, 16837 (2017).","journal-title":"Sci. Rep."},{"key":"67608_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102539","volume":"298","author":"S Irwin","year":"2022","unstructured":"Irwin, S. et al. Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARgamma by inverse agonists. J. Biol. Chem. 298, 102539 (2022).","journal-title":"J. Biol. Chem."},{"key":"67608_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14750-x","volume":"11","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. A molecular switch regulating transcriptional repression and activation of PPARgamma. Nat. Commun. 11, 956 (2020).","journal-title":"Nat. Commun."},{"key":"67608_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.117130","volume":"78","author":"DL Orsi","year":"2023","unstructured":"Orsi, D. L. et al. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists. Bioorg. Med Chem. 78, 117130 (2023).","journal-title":"Bioorg. Med Chem."},{"key":"67608_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/wics.101","volume":"2","author":"H Abdi","year":"2010","unstructured":"Abdi, H. & Williams, L. J. Principal component analysis. WIREs Comput. Stat. 2, 433\u2013459 (2010).","journal-title":"WIREs Comput. Stat."},{"key":"67608_CR41","doi-asserted-by":"crossref","unstructured":"Cave, E. & Crowther, N. J. The use of 3T3-L1 murine preadipocytes as a model of adipogenesis. in Pre-Clinical Models: Techniques and Protocols (ed. Guest, P. C.) 263\u2013272 (Springer New York, 2019).","DOI":"10.1007\/978-1-4939-8994-2_25"},{"key":"67608_CR42","doi-asserted-by":"publisher","first-page":"e47172","DOI":"10.7554\/eLife.47172","volume":"8","author":"TS Strutzenberg","year":"2019","unstructured":"Strutzenberg, T. S. et al. HDX-MS reveals structural determinants for RORgamma hyperactivation by synthetic agonists. Elife 8, e47172 (2019).","journal-title":"Elife"},{"key":"67608_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/(SICI)1521-3773(19990115)38:1\/2<236::AID-ANIE236>3.0.CO;2-M","volume":"38","author":"X Daura","year":"1999","unstructured":"Daura, X. et al. Peptide folding: when simulation meets experiment. Angew. Chem. Int. Ed. 38, 236\u2013240 (1999).","journal-title":"Angew. Chem. Int. Ed."},{"key":"67608_CR44","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/bioinformatics\/btl461","volume":"22","author":"BJ Grant","year":"2006","unstructured":"Grant, B. J., Rodrigues, A. P. C., ElSawy, K. M., McCammon, J. A. & Caves, L. S. D. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 22, 2695\u20132696 (2006).","journal-title":"Bioinformatics"},{"key":"67608_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/prot.340110305","volume":"11","author":"T Ichiye","year":"1991","unstructured":"Ichiye, T. & Karplus, M. Collective motions in proteins - a covariance analysis of atomic fluctuations in molecular-dynamics and normal mode simulations. Proteins-Struct. Funct. Genet. 11, 205\u2013217 (1991).","journal-title":"Proteins-Struct. Funct. Genet."},{"key":"67608_CR46","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1073\/pnas.1523573113","volume":"113","author":"U Doshi","year":"2016","unstructured":"Doshi, U., Holliday, M. J., Eisenmesser, E. Z. & Hamelberg, D. Dynamical network of residue-residue contacts reveals coupled allosteric effects in recognition, catalysis, and mutation. Proc. Natl. Acad. Sci. USA 113, 4735\u20134740 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67608_CR47","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.csbj.2016.06.002","volume":"14","author":"KF O\u2019Rourke","year":"2016","unstructured":"O\u2019Rourke, K. F., Gorman, S. D. & Boehr, D. D. Biophysical and computational methods to analyze amino acid interaction networks in proteins. Comput. Struct. Biotec. 14, 245\u2013251 (2016).","journal-title":"Comput. Struct. Biotec."},{"key":"67608_CR48","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.2337\/db17-1236","volume":"67","author":"M Agostini","year":"2018","unstructured":"Agostini, M. et al. A pharmacogenetic approach to the treatment of patients with PPARG mutations. Diabetes 67, 1086\u20131092 (2018).","journal-title":"Diabetes"},{"key":"67608_CR49","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.2337\/diabetes.51.12.3586","volume":"51","author":"RA Hegele","year":"2002","unstructured":"Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586\u20133590 (2002).","journal-title":"Diabetes"},{"key":"67608_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.830708","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Case report: a new peroxisome proliferator-activated receptor gamma mutation causes familial partial lipodystrophy type 3 in a chinese patient. Front. Endocrinol. (Lausanne) 13, 830708 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"67608_CR51","doi-asserted-by":"publisher","first-page":"7660","DOI":"10.1111\/jcmm.15401","volume":"24","author":"H Shoaito","year":"2020","unstructured":"Shoaito, H. et al. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration. J. Cell Mol. Med. 24, 7660\u20137669 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"67608_CR52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/00325481.2015.1015927","volume":"127","author":"S Bindlish","year":"2015","unstructured":"Bindlish, S., Presswala, L. S. & Schwartz, F. Lipodystrophy: syndrome of severe insulin resistance. Postgrad. Med. 127, 511\u2013516 (2015).","journal-title":"Postgrad. Med."},{"key":"67608_CR53","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1210\/jc.2007-2356","volume":"93","author":"GD Tan","year":"2008","unstructured":"Tan, G. D. et al. Fatty acid metabolism in patients with PPARgamma mutations. J. Clin. Endocrinol. Metab. 93, 4462\u20134470 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"67608_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-7-3","volume":"7","author":"GA Francis","year":"2006","unstructured":"Francis, G. A. et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7, 3 (2006).","journal-title":"BMC Med. Genet."},{"key":"67608_CR55","doi-asserted-by":"publisher","first-page":"16489","DOI":"10.1021\/acs.est.1c04318","volume":"55","author":"C Garoche","year":"2021","unstructured":"Garoche, C. et al. Interspecies differences in activation of peroxisome proliferator-activated receptor gamma by pharmaceutical and environmental chemicals. Environ. Sci. Technol. 55, 16489\u201316501 (2021).","journal-title":"Environ. Sci. Technol."},{"key":"67608_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.561256","volume":"11","author":"MMG Dias","year":"2020","unstructured":"Dias, M. M. G. et al. PPARgamma S273 phosphorylation modifies the dynamics of coregulator proteins recruitment. Front. Endocrinol. (Lausanne) 11, 561256 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"67608_CR57","doi-asserted-by":"publisher","unstructured":"Coutos-Th\u00e9venot, L. et al. PPARg is a tumor suppressor in basal bladder tumors offering new potential therapeutic opportunities. Preprint at bioRxiv. https:\/\/doi.org\/10.1101\/868190 (2019).","DOI":"10.1101\/868190"},{"key":"67608_CR58","doi-asserted-by":"publisher","first-page":"21839","DOI":"10.1016\/S0021-9258(18)54714-1","volume":"266","author":"JM Stephens","year":"1991","unstructured":"Stephens, J. M. & Pekala, P. H. Transcriptional repression of the GLUT4 and C\/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J. Biol. Chem. 266, 21839\u201321845 (1991).","journal-title":"J. Biol. Chem."},{"key":"67608_CR59","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1021\/jasms.4c00202","volume":"35","author":"KC Kihn","year":"2024","unstructured":"Kihn, K. C. et al. Integration of hydrogen-deuterium exchange mass spectrometry with molecular dynamics simulations and ensemble reweighting enables high resolution protein-ligand modeling. J. Am. Soc. Mass Spectrom. 35, 2714\u20132728 (2024).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"67608_CR60","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1074\/mcp.RA117.000308","volume":"16","author":"VQ Lam","year":"2017","unstructured":"Lam, V. Q., Zheng, J. & Griffin, P. R. Unique interactome network signatures for peroxisome proliferator-activated receptor gamma (PPARgamma) modulation by functional selective ligands. Mol. Cell Proteom. 16, 2098\u20132110 (2017).","journal-title":"Mol. Cell Proteom."},{"key":"67608_CR61","doi-asserted-by":"publisher","first-page":"12060","DOI":"10.3390\/ijms252212060","volume":"25","author":"A Hummadi","year":"2024","unstructured":"Hummadi, A. et al. Genomic and bioinformatics analysis of familial partial lipodystrophy type 3 identified in a patient with novel PPARgamma mutation and robust response to pioglitazone. Int. J. Mol. Sci. 25, 12060 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"67608_CR62","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/ATVBAHA.112.300962","volume":"33","author":"M Auclair","year":"2013","unstructured":"Auclair, M. et al. Peroxisome proliferator-activated receptor-gamma mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Arterioscler Thromb. Vasc. Biol. 33, 829\u2013838 (2013).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"67608_CR63","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/QAD.0b013e328339e274","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat, M. et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24, 1291\u20131298 (2010).","journal-title":"AIDS"},{"key":"67608_CR64","doi-asserted-by":"publisher","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw. Open 7, e2413172 (2024).","journal-title":"JAMA Netw. Open"},{"key":"67608_CR65","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/sj.ki.5001620","volume":"70","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis, P. A. & Bakris, G. L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 70, 1223\u20131233 (2006).","journal-title":"Kidney Int."},{"key":"67608_CR66","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0189","author":"DJ Sanchez","year":"2021","unstructured":"Sanchez, D. J., Missiaen, R., Skuli, N., Steger, D. J. & Simon, M. C. Cell-Intrinsic tumorigenic functions of ppargamma in bladder urothelial carcinoma. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0189 (2021).","journal-title":"Mol. Cancer Res."},{"key":"67608_CR67","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-17-1701","volume":"77","author":"JT Goldstein","year":"2017","unstructured":"Goldstein, J. T. et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 77, 6987\u20136998 (2017).","journal-title":"Cancer Res."},{"key":"67608_CR68","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11914-021-00679-7","volume":"19","author":"M Adhikari","year":"2021","unstructured":"Adhikari, M. & Delgado-Calle, J. Role of osteocytes in cancer progression in the bone and the associated skeletal disease. Curr. Osteoporos. Rep. 19, 247\u2013255 (2021).","journal-title":"Curr. Osteoporos. Rep."},{"key":"67608_CR69","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1021\/ac051294f","volume":"78","author":"MJ Chalmers","year":"2006","unstructured":"Chalmers, M. J. et al. Probing protein ligand interactions by automated hydrogen\/deuterium exchange mass spectrometry. Anal. Chem. 78, 1005\u20131014 (2006).","journal-title":"Anal. Chem."},{"key":"67608_CR70","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/pro.5560020404","volume":"2","author":"Z Zhang","year":"1993","unstructured":"Zhang, Z. & Smith, D. L. Determination of amide hydrogen exchange by mass spectrometry: a new tool for protein structure elucidation. Protein Sci. 2, 522\u2013531 (1993).","journal-title":"Protein Sci."},{"key":"67608_CR71","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s13361-012-0419-6","volume":"23","author":"BD Pascal","year":"2012","unstructured":"Pascal, B. D. et al. HDX workbench: software for the analysis of H\/D exchange MS data. J. Am. Soc. Mass Spectrom. 23, 1512\u20131521 (2012).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"67608_CR72","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock vina 1.2.0: new docking methods, expanded force field, and Python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"67608_CR73","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"67608_CR74","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1021\/acs.jcim.3c01053","volume":"63","author":"M Bugnon","year":"2023","unstructured":"Bugnon, M. et al. SwissParam 2023: a modern web-based tool for efficient small molecule parametrization. J. Chem. Inf. Model. 63, 6469\u20136475 (2023).","journal-title":"J. Chem. Inf. Model."},{"key":"67608_CR75","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.21816","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete, V., Cuendet, M. A., Grosdidier, A. & Michielin, O. SwissParam: a fast force field generation tool for small organic molecules. J. Comput. Chem. 32, 2359\u20132368 (2011).","journal-title":"J. Comput. Chem."},{"key":"67608_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"67608_CR77","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."},{"key":"67608_CR78","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"67608_CR79","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671\u2013690 (2010).","journal-title":"J. Comput. Chem."},{"key":"67608_CR80","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1063\/1.445869","volume":"79","author":"WL Jorgensen","year":"1983","unstructured":"Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water.  J. Chem. Phys. 79, 926\u2013935 (1983).","journal-title":"J. Chem. Phys."},{"key":"67608_CR81","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463\u20131472 (1997).","journal-title":"J. Comput. Chem."},{"key":"67608_CR82","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., Vangunsteren, W. F., Dinola, A. & Haak, J. R. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"67608_CR83","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","volume":"52","author":"M Parrinello","year":"1981","unstructured":"Parrinello, M. & Rahman, A. Polymorphic transitions in single-crystals - a new molecular-dynamics method. J. Appl Phys. 52, 7182\u20137190 (1981).","journal-title":"J. Appl Phys."},{"key":"67608_CR84","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh ewald - an N.Log(N) method for ewald sums in large systems. J. Chem. Phys. 98, 10089\u201310092 (1993).","journal-title":"J. Chem. Phys."},{"key":"67608_CR85","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bpj.2015.08.015","volume":"109","author":"RT McGibbon","year":"2015","unstructured":"McGibbon, R. T. et al. MDTraj: a modern open library for the analysis of molecular dynamics trajectories. Biophys. J. 109, 1528\u20131532 (2015).","journal-title":"Biophys. J."},{"key":"67608_CR86","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","volume":"585","author":"Harris","year":"2020","unstructured":"Harris et al. Array programming with NumPy. Nature 585, 357\u2013362 (2020).","journal-title":"Nature"},{"key":"67608_CR87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3102\/1076998619832248","volume":"44","author":"JG Hao","year":"2019","unstructured":"Hao, J. G. & Ho, T. K. Machine learning made easy: a review of scikit-learn package in Python programming language. J. Educ. Behav. Stat. 44, 348\u2013361 (2019).","journal-title":"J. Educ. Behav. Stat."},{"key":"67608_CR88","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn Res."},{"key":"67608_CR89","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"67608_CR90","doi-asserted-by":"publisher","unstructured":"Waskom, M. seaborn: statistical data visualization. J. Open Source Softw. https:\/\/doi.org\/10.21105\/joss.03021 (2021).","DOI":"10.21105\/joss.03021"},{"key":"67608_CR91","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Valdes-Tresanco","year":"2021","unstructured":"Valdes-Tresanco, M. S., Valdes-Tresanco, M. E., Valiente, P. A. & Moreno, E. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281\u20136291 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"67608_CR92","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"67608_CR93","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency.  Ann. Stat. 29, 1165\u20131188 (2001).","journal-title":"Ann. Stat."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67608-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:03:37Z","timestamp":1769223817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67608-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67608"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67608-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.R.G. and T.M.K. are inventors on patents related to these studies. These patents are assigned to the University of Florida and have been licensed to Synkine Therapeutics, Inc. P.R.G. and T.M.K. also hold equity options in Synkine Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"890"}}